Approved in 1999, Avandia was developed to control blood sugar levels in diabetics by making patients more sensitive to their own insulin. It is one of a class of three drugs, the first of which, Rezulin, was withdrawn because it caused liver damage. 

One study estimated that from 1999 to 2009, more than 47,000 people taking Avandia needlessly suffered a heart attack, stroke or heart failure, or died.

Senate investigators found that GlaxoSmithKline spent years hiding from regulatory authorities clear indications that Avandia increased heart risks. In July 2010, GlaxoSmithKline took a $2.3 billion liability charge related to legal cases involving Avandia and another medicine (Paxil).

Today, in the United States, Avandia use is severely restricted by the FDA. Patients are allowed access to the medicine only if they and their doctors attest that they have tried every other diabetes medicine and that patients have been made aware of the drug's substantial risks to the heart.

GoldenbergLaw has successfully represented victims of pharmaceutical negligence for over 25 years. The Avandia cases GoldenbergLaw has taken on are no exception. GoldenbergLaw has successfully resolved its Avandia lawsuits for its clients. Avandia has lost most of its market share and has been discredited by these lawsuits.